NYSE: GSK

Explore the latest insights on NYSE: GSK and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NYSE: GSK’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Shandong Lukang Wins NMPA Registration for Generic Cefuroxime Sodium for Injection – Entering a RMB 2.6 Billion Chinese Cephalosporin Market
CompanyDrug

Shandong Lukang Wins NMPA Registration for Generic Cefuroxime Sodium for Injection – Entering a RMB 2.6 Billion Chinese Cephalosporin Market

Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that it has received Drug Registration Certificates (Certificate Nos. 2026S03571 and 2026S03572) from China's National Medical Products Administration (NMPA) for Cefuroxime Sodium…

Xunfei Healthcare Establishes Hainan Xunfei Internet Hospital Subsidiary with RMB 10 Million Registered Capital – Extending Digital Healthcare Footprint in Hainan Free Trade Port

Xunfei Healthcare Establishes Hainan Xunfei Internet Hospital Subsidiary with RMB 10 Million Registered Capital – Extending Digital Healthcare Footprint in Hainan Free Trade Port

CSPC's Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company's First Recombinant Protein Vaccine Candidate to Enter Clinical Trials

CSPC’s Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company’s First Recombinant Protein Vaccine Candidate to Enter Clinical Trials

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
GSK's Nucala Accepted for EMA Review for COPD Treatment
CompanyDrug

GSK’s Nucala Accepted for EMA Review for COPD Treatment

GSK's Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic
CompanyDrug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

GSK's Nucala Receives NMPA Review for COPD Treatment
CompanyDrug

GSK’s Nucala Receives NMPA Review for COPD Treatment

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines
Company

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines

GSK's Jemperli Approved for First-Line Endometrial Cancer Treatment in EU
CompanyDrug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline
CompanyDeals

GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline

Ouro Medicines Launches with $120M Series A Financing for CM336 Development
CompanyDeals

Ouro Medicines Launches with $120M Series A Financing for CM336 Development

GSK's Shingrix Prefilled Syringe Accepted for FDA Review
CompanyDrug

GSK’s Shingrix Prefilled Syringe Accepted for FDA Review

Show More